Wells Fargo & Company Cardiol Therapeutics Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 2,000 shares of CRDL stock, worth $3,120. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,000
Previous 3,000
33.33%
Holding current value
$3,120
Previous $6,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CRDL
# of Institutions
45Shares Held
5.07MCall Options Held
5.2KPut Options Held
9.5K-
Tejara Capital LTD London, X01.77MShares$2.76 Million1.67% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD1.17MShares$1.83 Million0.46% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9796KShares$1.24 Million0.36% of portfolio
-
Lion Street Advisors, LLC273KShares$426,3180.19% of portfolio
-
Foundations Investment Advisors, LLC162KShares$252,6420.01% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $96.6M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...